Morgan Stanley Raises Price Targets on UnitedHealth and Kymera Therapeutics
Morgan Stanley lifted its UnitedHealth price target to $531 from $529 and Kymera Therapeutics to $146 from $135, keeping Overweight ratings.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
On October 27, Morgan Stanley raised its price target on UnitedHealth to $531 from $529 and kept its Overweight rating. According to Dow Jones Newswires, citing Benzinga, the bank also raised its Kymera Therapeutics target to $146 from $135 the same day, while maintaining an Overweight rating.
Both changes concern only analyst price targets and ratings, not the companies' actual share prices. The UnitedHealth report was published at 11:41 GMT and the Kymera Therapeutics report at 12:57 GMT.
why it matters
Revisions like these reflect the analysts' updated view rather than new facts from company filings. An Overweight rating signals that the bank expects the shares to outperform the broader market. For the market, the signal is modest: small target increases like these rarely move the stocks noticeably.
tags
instruments
sources
- UnitedHealth Price Target Raised to $531.00/Share From $529.00 by Morgan Stanley — Dow Jones Newswires, 27 October 2026 at 11:41 UTC
- Kymera Therapeutics Price Target Raised to $146.00/Share From $135.00 by Morgan Stanley — Dow Jones Newswires, 27 October 2026 at 12:57 UTC
- Planet Fitness Price Target Raised to $55.00/Share From $51.00 by Morgan Stanley — Dow Jones Newswires, 27 October 2026 at 13:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗